Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer (SOFIA)

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT00548899
First received: October 23, 2007
Last updated: May 2, 2012
Last verified: September 2010

October 23, 2007
May 2, 2012
November 2007
September 2011   (final data collection date for primary outcome measure)
to establish the most feasible regimen of EC-P (P-EC) with sorafenib [ Time Frame: Time of surgery ] [ Designated as safety issue: No ]
Rate of histopathological complete remission at the time of surgery [ Time Frame: Time of surgery ]
Complete list of historical versions of study NCT00548899 on ClinicalTrials.gov Archive Site
  • Safety of preoperative regimen [ Time Frame: Treatment to Surgery ] [ Designated as safety issue: Yes ]
  • Determine clinical response rate [ Time Frame: Time of surgery ] [ Designated as safety issue: No ]
  • Histopathological axillary nodal status after neoadjuvant therapy [ Time Frame: Time of surgery ] [ Designated as safety issue: No ]
  • Correlate baseline and change in tumor and serum genetic, gene expression and proteomic patterns with clinical and pathological response [ Time Frame: Baeline till time of surgery ] [ Designated as safety issue: No ]
  • pCR rate at surgery [ Time Frame: Treatment ot Surgery ] [ Designated as safety issue: No ]
  • • Safety of preoperative regimen [ Time Frame: Treatment and 5 year follow up ]
  • Determine clinical response rate [ Time Frame: Time of surgery ]
  • Histopathological axillary nodal status after neoadjuvant therapy [ Time Frame: Time of surgery ]
  • Correlate baseline and change in tumor and serum genetic, gene expression and proteomic patterns with clinical and pathological response [ Time Frame: Baeline till time of surgery ]
  • Disease free and overall survival [ Time Frame: Treatment and 5 year follow up ]
Not Provided
Not Provided
 
Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer
Phase II Study of Neoadjuvant Epirubicin, Cyclophosphamide (EC) + Sorafenib Followed by Paclitaxel (P) + Sorafenib in Women With Previously Untreated

The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer

Epirubicin/Cyclophosphamide followed by Paclitaxel (EC/P) is a well tolerated regimen with high clinical activity. Histopathological complete remission after preoperative chemotherapy has a direct correlation with the disease-free and overall survival. The aim of combining a chemotherapy regime with sorafenib in the neoadjuvant setting is to increase the locoregional and systemic outcome of these patients

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
Drug: Nexavar (Sorafenib)
Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
Sorafenib
Single Arm: All patients receive sorafenib in addition to the established chemotherapy
Intervention: Drug: Nexavar (Sorafenib)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
December 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Unilateral or bilateral primary carcinoma of the breast,
  • Tumor lesion in the breast with a palpable size of >= 2 cm. The lesion has to be measurable in two-dimensions preferably by sonography. In case of inflammatory disease the extent of inflammation can be used as measurable lesion;
  • Patients should have stages of disease in which adjuvant chemotherapy would be considered.
  • Women of childbearing potential must have a negative serum pregnancy test
  • Negative HER-2/neu status
  • Karnofsky Performance status index >= 80%;
  • Normal cardiac function
  • Laboratory requirements:

Absolute neutrophile count (ANC) >= 2,0 x 109/L and Platelets >= 100 x 109/L and Hemoglobin >= 10 g/dL (>= 6.2 mmol/L) INR ≤ 1.5 ULN and PTT ≤ 1.5 ULN within 14 days prior to enrolment ASAT or ALAT < 2.5 x ULN Alkaline phosphatase ≤ 5 UNL. Patients with ASAT and/or ALAT > 1,5 x UNL associated with alkaline phosphatase > 2,5 x UNL are not eligible for the study Total bilirubin < 1 X UNL Creatinine ≤ 175 µmol/L (2 mg/dl). The calculated creatinine clearance should be ≥ 60 mL/min.

Paraffin tumor tissue block and each one serum and one plasma sample centrally made available

  • Complete staging work-up within 3 months prior to registration.
  • Patients must be available and compliant for treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating or a cooperating center.

Exclusion Criteria:

  • Patients with low or moderate risk, which are only doubtful candidates for adjuvant chemotherapy and do not fulfil the inclusion criteria No. 5.
  • Evidence of distant metastasis;
  • Prior chemotherapy for any malignancy;
  • Prior radiation therapy for breast cancer;
  • Preexisting rhagades at hand and feet and other skin problems (e.g. psoriasis)
  • Pregnant or lactating patients.
  • Pre-existing motor or sensory neuropathy of a severity >= grade 2 by NCI criteria; 7. Concurrent treatment with: Chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (< 20 mg methylprednisolone or equivalent); Sex hormones. Prior treatment must be stopped before study entry; Patients with increased risk of bleeding due to concurrent therapeutic or prophylactic anticoagulative treatment. Low dose of coumarines are permitted.

Other experimental drugs or any other anti-cancer therapy; Drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days or their expected need 8. Other serious illness or medical condition:

  • Previous malignant disease without being disease-free of less than 5 years (except CIS of the Cervix and non-melanomatous skin cancer)
  • Known or suspected congestive heart failure (≥NYHA II) and/or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension, rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease
  • Thrombotic or embolic events
  • Hemorrhage/bleeding event ≥ Grade 3 within 4 weeks prior study entry
  • Evidence or history of bleeding diathesis or coagulopathy
  • History of significant neurological or psychiatric disorders
  • Patients with seizure disorders requiring medication such as steroids or antiepileptics
  • Currently active infection
  • History of HIV infection or chronic hepatitis B or C
  • Serious non healing wound, ulcer or bone fracture
  • Patients with prior immunosuppressive treatment
  • Severe pulmonary condition/illness
  • Disease significantly affecting gastrointestinal function,
  • Patients with severe liver disease
  • Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
  • Definite contraindications for the use of corticosteroids
  • Inadequate general condition (not fit for anthracycline/taxane-containing chemotherapy)
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00548899
GBG 45, 2007-000124-41
Yes
German Breast Group
German Breast Group
Bayer
Study Chair: Sibylle Loibl, MD GBG Forschungs GmbH
German Breast Group
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP